Lauren Buchholz, NP
Adult Health · Englewood, CONPI 1902314503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,111 and has fallen 82.3% since, to $196 in 2025. Among adult health clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$553
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$351
- AstraZeneca$328
- Pfizer$273
- Novartis$245
- Boehringer Ingelheim$206
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,456100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 29 | $553 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $351 |
| AstraZeneca | 14 | $328 |
| Pfizer | 13 | $273 |
| Novartis | 12 | $245 |
| Boehringer Ingelheim | 5 | $206 |
| Actelion Pharmaceuticals US, Inc. | 9 | $186 |
| Lexicon Pharmaceuticals, Inc. | 3 | $156 |
| E.r. Squibb & Sons, L.L.C. | 8 | $152 |
| Medtronic | 1 | $141 |
| Merck | 8 | $133 |
| Kestra Medical Technology Services, Inc. | 4 | $114 |
| Cvrx, Inc. | 1 | $74 |
| Amarin Pharma, Inc. | 4 | $68 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Abiomed | 1 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Chiesi USA, Inc. | 1 | $36 |
| Impulse Dynamics (USA) Inc. | 2 | $33 |
| Abbott | 1 | $32 |
| Boston Scientific | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Veryan Medical Incorporated | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Heartflow, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Bayer | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$141
- JARDIANCE$122
- Inpefa$121
- Repatha$120
- FARXIGA$111
How this compares
$3,456 in reported general payments places this provider in the 90th percentile of 430 adult health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $69,073 |
| EntrestoSacubitril/Valsartan | 13 | $23,505 |
| Repatha SureclickEvolocumab | 18 | $12,634 |
| NexletolBempedoic Acid | 16 | $9,163 |
| FarxigaDapagliflozin Propanediol | 11 | $8,535 |
| Praluent PenAlirocumab | 12 | $7,026 |
| Ranolazine ErRanolazine | 14 | $1,642 |
| Atorvastatin Calcium | 113 | $1,297 |
| Ezetimibe | 24 | $1,093 |
| Rosuvastatin Calcium | 83 | $1,058 |
| Losartan Potassium | 95 | $1,043 |
| ClopidogrelClopidogrel Bisulfate | 67 | $895 |
| Carvedilol | 85 | $754 |
| Metoprolol Succinate | 39 | $674 |
| Metoprolol Tartrate | 62 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $273 | $69,07344 claims |
| NovartisEntresto | $245 | $23,50513 claims |
| AstraZenecaFarxiga | $328 | $8,53511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 430 adult health providers in Colorado.
Other adult health in Englewood
- Abbey JonesEnglewood$11K
- Nicole GoitiaEnglewood$11K
- Brittany DelmonicoEnglewood$3K
- Stefanie EymarAurora$36K
- Jamie ThompsonColorado Springs$31K
- Toni StandleyDenver$23K
- Alexandra GravesAurora$18K
- Keri HalsemaAurora$17K
- Grace WorlandAurora$11K
- Carolyn SchniedersLittleton$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.